ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
This is a non-randomized phase 1 trial designed to determine the MTD and evaluate the safety
and tolerability of ACY-1215 with nab-paclitaxel. Based on the activity profile of ACY-1215
in breast cancer, corresponding biomarker availability with the HDAC6 MR score, and its
potential synergy with taxanes, these data support the rationale for testing the ability of
ACY-1215 to improve the response rate for patients with metastatic breast cancer in
combination with standard taxane chemotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
Columbia University Kevin Kalinsky
Collaborators:
Acetylon Pharmaceuticals Incorporated National Cancer Institute (NCI)